The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Open accessAbstract
Cancer-associated IDH mutations are characterized by neomorphic enzyme activity and resultant 2-hydroxyglutarate (2HG) production. Mutational and epigenetic profiling of a large acute myeloid leukemia (AML) patient cohort revealed that IDH1/2-mutant AMLs display global DNA hypermethylation and a specific hypermethylation signature. Furthermore, expression of 2HG-producing IDH alleles in cells induced global DNA hypermethylation. In the AML cohort, IDH1/2 mutations were mutually exclusive with mutations in the α-ketoglutarate-dependent enzyme TET2, and TET2 loss-of-function mutations were associated with similar epigenetic defects as IDH1/2 mutants. Consistent with these genetic and epigenetic data, expression of IDH mutants impaired TET2 catalytic function in cells. Finally, either expression of mutant IDH1/2 or Tet2 depletion impaired hematopoietic differentiation and increased stem/progenitor cell marker expression, suggesting a shared proleukemogenic effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [153]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistently, TET2-mutant immature and myeloid cells present with hypermethylation of active enhancers and perturbed TF activity (28, 32, 53).”
From PU.1-Dependent Enhancer Inhibition Separates Tet2 -Deficient Hematopoiesis from Malignant Transformation (2022) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [4]
In the citing paper
“As a result, D-2HG accumulation in cancer cells expressing mutant IDH results in hypermethylation of histones and CpG islands in DNA (Figueroa et al., 2010; Lu et al., 2012; Turcan et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Figueroa et al., 2010
In the citing paper
“Mutations in isocitrate dehydrogenase isoform-1 (IDH1) and IDH2 generate the oncometabolite D-2-hydroxyglutarate (D-2HG), which inhibits epigenetic enzymes including histone demethylases and the Ten-eleven translocation (TET) family of 5-methylcytosine hydroxylases.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [25]
In the citing paper
“These effects contribute to tumor initiation in acute myelogenous leukemia (AML) by resulting in persistent histone and DNA methylation and impaired cellular differentiation (25).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [25]
In the citing paper
“The role of R-2-HG as an oncometabolite has been implicated in epigenetic modifications through the inhibition of α-KG-dependent dioxygenases and demethylases”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [117]
In the citing paper
“In addition, TET2 inactivation is sufficient to promote hematopoietic stem cell self-renewal and to block differentiation (Figueroa et al., 2010; Li et al., 2011; Moran-Crusio et al., 2011; Noushmehr et al., 2010; Turcan et al., 2012; Losman et al., 2013).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“In this regard, TET2 and IDH mutations are both found in acute myelogenous leukemia and are mutually exclusive, consistent with the idea that R-2HG produced by mutant IDH provides an alterative means of inactivating TET2 (Figueroa et al., 2010).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“R-2HG, succinate, and fumarate are all capable of inhibiting multiple 2-oxoglutarate-dependent dioxygenases, including the JmjC histone demethylases and TET proteins, when present at sufficiently high concentrations (Figure 6B) (Cervera et al., 2009; Chowdhury et al., 2011; Figueroa et al., 2010; Koivunen et al., 2012; Lu et al., 2012; Smith et al., 2007; Turcan et al., 2012; Xiao et al., 2012; Xu”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“More recently, we have also learnt how the catalytic activity of EZH2 can be compromised by so called 'oncohistones' 100 (Figure 3).”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [100]
In the citing paper
“Around 30% of all paediatric glioblastomas contain mutations in histone genes resulting in H3K27M, H3K27I and H3G34V/R substitutions (reviewed in REF. 100 ).”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [100]
In the citing paper
“in a large acute myelogenous leukaemia (AML) cohort, TET2 was found to be mutually exclusive with gain-of-function mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 (REF.65).”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [65]
In the citing paper
“Heterozygous, inactivating ten-eleven translocation 2 (TET2) mutations and neomorphic isocitrate dehydrogenase (IDH) mutations are recurrent and mutually exclusive in acute myeloid leukaemia genomes.”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [5]
In the citing paper
“By blocking the enzymatic activity of histone and DNA demethylases, d-2HG can function to lock cells in a hypermethylated state that blocks differentiation and reinforces a malignant and stem cell–like phenotype (30, 172, 173, 174).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [172]
In the citing paper
“Indeed, IDH-driven gliomas, leukemias and chondrosarcomas display a prominent CpG island hypermethylation, reminiscent of the hypermethylator phenotype seen in SDH- and FH-deficient cancers (Figueroa et al., 2010; Lu et al., 2013; Turcan et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Figueroa et al., 2010
In the citing paper
“IDH mutations in AML are mutually exclusive with inactivating mutations in TET2 methylcytosine hydroxylases, further implicating mutant IDH as a bona fide driver of epigenetic remodeling (Figueroa et al., 2010).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Figueroa et al., 2010
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“Mutant IDH2 [Arg140→Gln140 (R140Q)], which promotes α-KG depletion/2-HG production, promotes DNA hypermethylation in hematopoietic cells and can inhibit myeloid differentiation when overexpressed in bone marrow stem cells (79).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“multiple groups have found that IDH mutant expression and 2HG elevation can inhibit the TET family of enzymes that hydroxylate 5’-methylcytosine (Figueroa et al., 2010; Turcan et al., 2012; Xu et al., 2011)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“TET2 mutant AML samples displayed an overlapping DNA hypermethylation signature with samples having IDH1 or IDH2 mutations”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“neomorphic mutations of IDH1 or IDH2 and TET2 loss-of-function mutations were found to be mutually exclusive in a large AML cohort”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“In both cell types, the overexpression of IDH mutants blocked acquisition of mature myeloid markers while increasing the expression of stem cell markers (Figueroa et al., 2010).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“shRNA knockdown of TET2 recapitulated the effect of IDH mutant overexpression on blocking hematopoietic cell differentiation (Figueroa et al., 2010)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“mutations in IDH1/2 and in the 5-methylcytosine hydroxylase TET2 occur frequently in acute myelogenous leukemia”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“primary IDH1- or IDH2-mutant tumors showed evidence of extensively altered histone and DNA methylation in vivo”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“the mutations were found to be mutually exclusive”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“high concentrations of 2-HG inhibited the function of α-ketoglutarate-dependent histone demethylases and 5-methylcytosine hydroxylases in vitro”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“metabolomic profiling of mIDH1/2 gliomas revealed significant alterations in cellular metabolism, an effect recapitulated with the exogenous addition of D-2-HG134.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [134]
In the citing paper
“This metabolic rewiring resulted in a decrease in a common dipeptide found in the brain N-acetyl-aspartyl-glutamate (NAAG), and NAAG levels were found to be significantly lower in IDH-mutant human glioma tissue134.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationIto, S., D’Alessio, A. C., Taranova, O., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,628
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Histone demethylation by a family of JmjC domain-containing proteins
Tsukada, Y.-I., Fang, J., Erdjument‐Bromage, H., Warren, M., Borchers, C. H., Tempst, P., & Zhang, Y. (2005) · Nature · doi:10.1038/nature04433 · Cited by 2,244
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Self-citation
Flagged first, then by citations
1 of the 35 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 801–900 of 1,005
Fathi, A. T., Kim, H. T., Soiffer, R. J., Levis, M. J., Li, S., Kim, A. S., Mims, A. S., DeFilipp, Z. M., El-Jawahri, A. R., McAfee, S. L., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008632 · Cited by 68
Thomas, D., Wu, M., Nakauchi, Y., Zheng, M., Thompson-Peach, C. A. L., Lim, K. S., Landberg, N., Köhnke, T., Robinson, N., Kaur, S., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0218 · Cited by 69
MiR-181a regulates lipid metabolism via IDH1
Chu, B., Wu, T. H., Miao, L., Mei, Y., & Wu, M. (2015) · Scientific Reports · doi:10.1038/srep08801 · Cited by 68
Brennan, K., Koenig, J. L., Gentles, A. J., Sunwoo, J. B., & Gevaert, O. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.02.025 · Cited by 67
Duchmann, M., Micol, J., Duployez, N., Raffoux, E., Thomas, X., Marolleau, J., Braun, T., Adès, L., Chantepie, S., Lemasle, É., et al. (2021) · Blood · doi:10.1182/blood.2020010165 · Cited by 66
Characteristics and prognostic impact ofIDHmutations in AML: a COG, SWOG, and ECOG analysis
Zarnegar‐Lumley, S., Alonzo, T. A., Gerbing, R. B., Othus, M. K. D., Sun, Z., Ries, R. E., Wang, J., Leonti, A. R., Kutny, M. A., Ostronoff, F., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008282 · Cited by 70
Self-citationGrossmann, V., Haferlach, C., Nadarajah, N., Fasan, A., Weißmann, S., Roller, A., Eder, C., Stopp, E., Kern, W., Haferlach, T., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12297 · Cited by 69
Loriot, A. E., Tongelen, A. V., Blanco, J., Klaessens, S., Cannuyer, J., van Baren, N., Decottignies, A., & Smet, C. D. (2014) · Epigenetics · doi:10.4161/epi.29628 · Cited by 66
High DNA Methyltransferase DNMT3B Levels: A Poor Prognostic Marker in Acute Myeloid Leukemia
Hayette, S., Thomas, X., Jallades, L., Chabane, K., Charlot, C., Tigaud, I., Gazzo, S., Morisset, S., Cornillet‐Lefèbvre, P., Pleșa, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051527 · Cited by 66
Stuani, L., Riols, F., Millard, P., Sabatier, M., Batut, A., Saland, E., Viars, F., Tonini, L., Zaghdoudi, S., Linares, L. K., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113325 · Cited by 72
Nagata, Y., Makishima, H., Kerr, C. M., Przychodzen, B. P., Aly, M. M., Goyal, A., Awada, H. K., Asad, M., Kuzmanovic, T., Suzuki, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13001-y · Cited by 69
Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism
Pollard, P. J., Yang, M. H., Su, H., Soga, T., & Kranc, K. R. (2014) · Hypoxia · doi:10.2147/hp.s47968 · Cited by 66
Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma
Mariño‐Enríquez, A., & Bovée, J. V. M. G. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.04.009 · Cited by 69
Lozada, J. R., Basili, T., Pareja, F. G., Alemar, B., Paula, A. D. C., Gularte‐Mérida, R., Giri, D. D., Querzoli, P., Cserni, G., Rakha, E. A., et al. (2018) · Histopathology · doi:10.1111/his.13522 · Cited by 65
Pandolfi, A., Barreyro, L., & Steidl, U. G. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0109 · Cited by 66
Kunimoto, H., Fukuchi, Y., Sakurai, M., Sadahira, K., Ikeda, Y., Okamoto, S., & Nakajima, H. (2012) · Scientific Reports · doi:10.1038/srep00273 · Cited by 71
Natsumeda, M., Igarashi, H., Nomura, T., Ogura, R., Tsukamoto, Y., Kobayashi, T., Aoki, H., Okamoto, K., Kakita, A., Takahashi, H., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0158-y · Cited by 64
Rinaldi, G., Rossi, M., & Fendt, S. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1397 · Cited by 65
DNMT3A mutations in acute myeloid leukemia
Shah, M. Y., & Licht, J. D. (2011) · Nature Genetics · doi:10.1038/ng0411-289 · Cited by 70
Self-citationLinking Metabolic Reprogramming, Plasticity and Tumor Progression
Shuvalov, O., Daks, A., Fedorova, O., Petukhov, A., & Barlev, N. (2021) · Cancers · doi:10.3390/cancers13040762 · Cited by 63
Konstandin, N. P., Bultmann, S., Szwagierczak, A., Dufour, A., Ksienzyk, B., Schneider, F., Herold, T., Mulaw, M. A., Kakadia, P. M., Schneider, S.-R., et al. (2011) · Leukemia · doi:10.1038/leu.2011.134 · Cited by 67
Chou, A. P., Chowdhury, R., Li, S., Chen, W., Kim, A. J., Piccioni, D. E., Selfridge, J. M., Mody, R. R., Chang, S., Lalezari, S., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs357 · Cited by 67
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
Ball, B. J., Zeidan, A. M., Gore, S. D., & Prébet, T. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1228927 · Cited by 64
The genomic and epigenomic landscape in thymic carcinoma
Saito, M., Fujiwara, Y., Asao, T., Honda, T., Shimada, Y., Kanai, Y., Tsuta, K., Kono, K., WATANABE, S.-I. I., Ohe, Y., et al. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx094 · Cited by 63
Mitochondrial redox and TCA cycle metabolite signaling in the heart
Vujić, A., Koo, A., Prag, H. A., & Krieg, T. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.02.041 · Cited by 62
Role of Epigenetic Regulation in Plasticity of Tumor Immune Microenvironment
Yang, Y., & Wang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.640369 · Cited by 64
Kubyshkin, V., & Rubini, M. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00007 · Cited by 64
IDH Mutations in Tumorigenesis and Their Potential Role As Novel Therapeutic Targets
Krell, D., Mulholland, P. J., Frampton, A. E., Krell, J., Stebbing, J., & Bardella, C. (2013) · Future Oncology · doi:10.2217/fon.13.143 · Cited by 63
A Zebrafish Model of Myelodysplastic Syndrome Produced through tet2 Genomic Editing
Gjini, E., Mansour, M. R., Sander, J. D., Moritz, N., Nguyen, A. T., Kesarsing, M., Gans, E., He, S., Chen, S., Ko, M., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00971-14 · Cited by 64
Normal and cancer cell metabolism: lymphocytes and lymphoma
Altman, B. J., & Dang, C. V. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08651.x · Cited by 66
On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer
Penkert, J., Ripperger, T., Schieck, M., Schlegelberger, B., Steinemann, D., & Illig, T. (2016) · Oncotarget · doi:10.18632/oncotarget.11759 · Cited by 64
Sun, X., Johnson, J. L., & John, J. C. S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky339 · Cited by 62
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies
Bergaggio, E., Riganti, C., Garaffo, G., Vitale, N., Mereu, E., Bandini, C., Pellegrino, E., Pullano, V., Omedè, P., Todoerti, K., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850826 · Cited by 62
Guan, Y., Tiwari, A. D., Phillips, J. G., Hasipek, M., Grabowski, D., Pagliuca, S., Gopal, P., Kerr, C. M., Ademà, V., Radivoyevitch, T., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0173 · Cited by 64
Recent advances in the understanding and treatment of acute myeloid leukemia
Watts, J. M., & Nimer, S. D. (2018) · F1000Research · doi:10.12688/f1000research.14116.1 · Cited by 61
The role of vitamin C in epigenetic cancer therapy
Mikkelsen, S. U., Gillberg, L., Lykkesfeldt, J., & Grønbæk, K. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.03.017 · Cited by 62
TET-catalyzed 5-methylcytosine hydroxylation is dynamically regulated by metabolites
Yang, H., Lin, H., Xu, H., Zhang, L., Cheng, L., Wen, B., Shou, J., Guan, K., Xiong, Y., & Ye, D. (2014) · Cell Research · doi:10.1038/cr.2014.81 · Cited by 61
Katoh, M. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1033409 · Cited by 65
Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable
Zoi, K., & Cross, N. C. P. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1670-3 · Cited by 62
Fernández‐Mercado, M., Yip, B. H., Pellagatti, A., Davies, C. H., Larráyoz, M. J., Kondo, T., Pérez, C., Killick, S. B., McDonald, E.-J., Odero, M. D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042334 · Cited by 64
Sulai, N. H., Jimma, T., Lasho, T. L., Finke, C. M., Knudson, R. A., McClure, R. F., Pardanani, A. D., & Tefferi, A. (2011) · Blood · doi:10.1182/blood.v118.21.1751.1751 · Cited by 61
Epigenetics in myelodysplastic syndromes
Heuser, M., Yun, H., & Thol, F. R. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.009 · Cited by 61
Control of the Antitumor Immune Response by Cancer Metabolism
Domblides, C., Lartigue, L., & Faustin, B. (2019) · Cells · doi:10.3390/cells8020104 · Cited by 64
Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
Liu, Y., Lang, F., Chou, F.-J., Zaghloul, K. A., & Yang, C. (2020) · Biomedicines · doi:10.3390/biomedicines8090294 · Cited by 62
Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy
Chen, C., Wang, Z., & Qin, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935536 · Cited by 62
Leca, J., Lemonnier, F., Meydan, C., Foox, J., Ghamrasni, S. E., Mboumba, D.-L., Duncan, G. S., Fortin, J., Sakamoto, T., Tobin, C., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.003 · Cited by 60
Self-citationThe role of mutations in epigenetic regulators in myeloid malignancies
Woods, B. A., & Levine, R. L. (2014) · Immunological Reviews · doi:10.1111/imr.12246 · Cited by 63
Self-citationLiu, Z., Yao, Y., Kogiso, M., Zheng, B., Deng, L., Qiu, J. J., Dong, S., Lv, H., Gallo, J. M., Li, X., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500660f · Cited by 60
Immunological effects of hypomethylating agents
Lindblad, K. E., Goswami, M., Hourigan, C. S., & Oetjen, K. A. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1346470 · Cited by 62
Mason, E. F., Kuo, F. C., Hasserjian, R. P., Seegmiller, A. C., & Pozdnyakova, O. (2017) · American Journal of Hematology · doi:10.1002/ajh.25018 · Cited by 60
The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia
Dalle, I. A., & Dinardo, C. D. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718777467 · Cited by 60
Acute Myeloid Leukemia: Aging and Epigenetics
Zjablovskaja, P., & Florian, M. C. (2019) · Cancers · doi:10.3390/cancers12010103 · Cited by 61
Taylor, J., Mi, X., North, K., Binder, M., Penson, A. V., Lasho, T. L., Knorr, K. L. B., Haddadin, M., Liu, B., Pangallo, J., et al. (2020) · Blood · doi:10.1182/blood.2020006868 · Cited by 62
Self-citationSun, Y., Chen, B.-R., & Deshpande, A. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00041 · Cited by 64
Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
Hvinden, I. C., Cadoux-Hudson, T. A. D., Schofield, C. J., & McCullagh, J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100469 · Cited by 63
Ahn, J., Kim, H., Kim, Y.-K., Lee, S.-S., Jung, S.-H., Yang, D.-H., Lee, J.-J., Kim, N. Y., Choi, S. H., Jung, C. W., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.07.030 · Cited by 61
From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma
Dunn, G. P., Andronesi, O. C., & Cahill, D. P. (2013) · Neurosurgical FOCUS · doi:10.3171/2012.12.focus12355 · Cited by 59
Genetics of Myeloproliferative Neoplasms
Viny, A. D., & Levine, R. L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000013 · Cited by 60
Self-citationNavis, A. C., Niclou, S. P., Fack, F., Stieber, D., van Lith, S. A. M., Verrijp, K. N., Wright, A. J., Stauber, J., Tops, B. B. J., Otte‐Höller, I., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-18 · Cited by 61
Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis
Eriksson, A., Lennartsson, A., & Lehmann, S. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.009 · Cited by 62
Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma
Agnihotri, S., Aldape, K., & Zadeh, G. M. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14505 · Cited by 59
The Application of Genome-Wide 5-Hydroxymethylcytosine Studies in Cancer Research
Thomson, J. P., & Meehan, R. R. (2016) · Epigenomics · doi:10.2217/epi-2016-0122 · Cited by 60
Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer
Koschmann, C. J., Núñez, F. J., Mendez, F., Brosnan‐Cashman, J. A., Meeker, A. K., Lowenstein, P. R., & Castro, M. G. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2301 · Cited by 60
Matteo, D. A., Grunseth, A. J., Gonzalez, E. R., Anselmo, S. L., Kennedy, M. A., Moman, P., Scott, D. A., Hoang, A. D., & Sohl, C. D. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.776179 · Cited by 62
Amon, S., Meier‐Abt, F., Gillet, L. C. J., Dimitrieva, S., Theocharides, A. P. A., Manz, M. G., & Aebersold, R. H. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir119.001431 · Cited by 60
TET-Mediated Epigenetic Regulation in Immune Cell Development and Disease
Tsiouplis, N. J., Bailey, D. W., Chiou, L. F., Wissink, F. J., & Tsagaratou, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.623948 · Cited by 63
Ogawara, Y., Katsumoto, T., Aikawa, Y., Shima, Y., Kagiyama, Y., Soga, T., Matsunaga, H., Seki, T., Araki, K., & Kitabayashi, I. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2200 · Cited by 58
Machida, Y., Nakagawa, M., Matsunaga, H., Yamaguchi, M., Ogawara, Y., Shima, Y., Yamagata, K., Katsumoto, T., Hattori, A., Itoh, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1349 · Cited by 60
DNA methylation changes in epithelial ovarian cancer histotypes
Earp, M. A., & Cunningham, J. M. (2015) · Genomics · doi:10.1016/j.ygeno.2015.09.001 · Cited by 58
Sasine, J. P., & Schiller, G. J. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.07.002 · Cited by 58
Epigenetic alterations in hematopoietic malignancies
Chung, Y. R., Schatoff, E. M., & Abdel-Wahab, O. I. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1181-z · Cited by 59
Self-citationNischal, S., Bhattacharyya, S., Christopeit, M., Yu, Y., Zhou, L., Bhagat, T. D., Sohal, D. P. S., Will, B., Mo, Y., Suzuki, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0735 · Cited by 58
Self-citationSomatic Alterations Contributing to Metastasis of a Castration-Resistant Prostate Cancer
Nickerson, M. L., Im, K. M., Misner, K., Tan, W., Lou, H., Gold, B., Wells, D. W., Bravo, H. C., Fredrikson, K. M., Harkins, T. T., et al. (2013) · Human Mutation · doi:10.1002/humu.22346 · Cited by 59
Liu, S., Jiang, J., Li, L., Amato, N. J., Wang, Z., & Wang, Y. (2015) · Environmental Science & Technology · doi:10.1021/acs.est.5b03386 · Cited by 58
Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia
Stuani, L., Sabatier, M., & Sarry, J. (2019) · BMC Biology · doi:10.1186/s12915-019-0670-4 · Cited by 66
The Acidic Brain—Glycolytic Switch in the Microenvironment of Malignant Glioma
Reuss, A. M., Groos, D., Buchfelder, M., & Savaskan, N. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115518 · Cited by 58
Mutant IDH in Gliomas: Role in Cancer and Treatment Options
Solomou, G., Finch, A., Asghar, A., & Bardella, C. (2023) · Cancers · doi:10.3390/cancers15112883 · Cited by 62
Epigenetic regulation of cancer stemness
Galassi, C., Manic, G., Esteller, M., Galluzzi, L., & Vitale, I. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02340-6 · Cited by 62
Hosoda, F., Arai, Y., Okada, N., Shimizu, H., Miyamoto, M., Kitagawa, N., Katai, H., Taniguchi, H., Yanagihara, K., Imoto, I., et al. (2014) · Oncogene · doi:10.1038/onc.2014.57 · Cited by 57
Lessons from next-generation sequencing analysis in hematological malignancies
Braggio, E., Egan, J. B., Fonseca, R., & Stewart, A. K. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.26 · Cited by 57
Epigenetics advancing personalized nanomedicine in cancer therapy
Liu, S. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.004 · Cited by 59
Conceptual Framework for Cutting the Pancreatic Cancer Fuel Supply
Le, A., Rajeshkumar, N. V., Maitra, A., & Dang, C. V. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0041 · Cited by 57
Ball, M., List, A. F., & Padron, E. (2016) · Blood · doi:10.1182/blood-2016-07-692988 · Cited by 63
Epigenetic therapies in acute myeloid leukemia: where to from here?
Fennell, K. A., Bell, C. C., & Dawson, M. A. (2019) · Blood · doi:10.1182/blood.2019003262 · Cited by 60
RNA-Binding Proteins in Acute Leukemias
Schuschel, K., Helwig, M., Hüttelmaier, S., Heckl, D., Klusmann, J., & Hoell, J. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103409 · Cited by 57
The DNA methylation landscape of hematological malignancies: an update
Blecua, P., Martinez‐Verbo, L., & Esteller, M. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12744 · Cited by 57
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Heuser, M., Palmisiano, N. D., Mantzaris, I., Mims, A. S., Dinardo, C. D., Silverman, L. R., Wang, E. S., Fiedler, W., Baldus, C. D., Schwind, S., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0996-5 · Cited by 59
Epigenetic regulation in the pathogenesis of non-melanoma skin cancer
Kashyap, M. P., Sinha, R., Mukhtar, M. S., & Athar, M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.009 · Cited by 57
Yasuda, T., Sanada, M., Kawazu, M., Kojima, S., Tsuzuki, S., Ueno, H., Iwamoto, E., Iijima‐Yamashita, Y., Yamada, T., Kanamori, T., et al. (2021) · Blood · doi:10.1182/blood.2021011921 · Cited by 60
Jia, J., Shi, Y., Chen, L., Lai, W., Yan, B., Jiang, Y., Xiao, D., Xi, S., Cao, Y., Liu, S., et al. (2017) · Theranostics · doi:10.7150/thno.21389 · Cited by 57
IDH Inhibitors in AML—Promise and Pitfalls
McMurry, H. S., Fletcher, L. B., & Traer, E. A. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00619-3 · Cited by 56
Clonal hematopoiesis and hematological malignancy
Dunn, W. G., McLoughlin, M. A., & Vassiliou, G. S. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180065 · Cited by 63
Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis.
Feng, J., Guo, X., Chen, Y., Wang, Z.-J., Cheng, Y.-P., & Tang, Y. (2012) · PubMed Central · Cited by 56
Epigenetic deregulation in pediatric acute lymphoblastic leukemia
Chatterton, Z., Morenos, L., Mechinaud, F. M., Ashley, D. M., Craig, J. M., Sexton‐Oates, A., Halemba, M. S., Parkinson-Bates, M., Ng, J., Morrison, D. J., et al. (2014) · Epigenetics · doi:10.4161/epi.27585 · Cited by 56
Metabolic circuits in neural stem cells
Kim, D., Rhee, I., & Paik, J. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1686-0 · Cited by 59
DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders
Sato, H., Wheat, J. C., Steidl, U. G., & Ito, K. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00187 · Cited by 59
Metabolic intermediates – Cellular messengers talking to chromatin modifiers
Nieborak, A., & Schneider, R. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.01.007 · Cited by 57
The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas
Reiter–Brennan, C., Semmler, L., & Klein, A. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.82642 · Cited by 57
Chen, Y.-C., Gotea, V., Margolin, G., & Elnitski, L. L. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005840 · Cited by 56
Genetics of Myelodysplastic Syndromes: New Insights
Graubert, T. A., & Walter, M. J. (2011) · Hematology · doi:10.1182/asheducation-2011.1.543 · Cited by 56
Metadata
- Authors
- Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., Tallman, M. S., Sun, Z., Wolniak, K., Peeters, J. K., Liu, W., Choe, S. E., Fantin, V. R., Paietta, E., Löwenberg, B., Licht, J. D., Godley, L. A., Delwel, R., Valk, P. J. M., Thompson, C. B., Levine, R. L., & Melnick, A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Abramson Cancer Center (US)
- Weill Cornell Medicine (US)
- University of Chicago (US)
- Moffitt Cancer Center (US)
- Harvard University (US)
- Northwestern University (US)
- Erasmus MC (NL)
- Agios Pharmaceuticals (United States) (US)
- Montefiore Medical Center (US)
- Corresponding author
- Thompson, Craig B.
- Levine, Ross L.
- Melnick, Ari
- ORCID
- Abdel-Wahab, Omar
- Ward, Patrick S.
- Patel, Jay
- Shih, Alan
- Li, Yushan
- Bhagwat, Neha
- Vasanthakumar, Aparna
- Fernandez, Hugo F.
- Tallman, Martin S.
- Sun, Zhuoxin
- Wolniak, Kristy
- Liu, Wei
- Choe, Sung E.
- Fantin, Valeria R.
- Paietta, Elisabeth
- Löwenberg, Bob
- Licht, Jonathan D.
- Godley, Lucy A.
- Delwel, Ruud
- Valk, Peter J.M.
- Thompson, Craig B.
- Levine, Ross L.
- Melnick, Ari
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 18
- Issue
- 6
- Pages
- 553-567
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4105845
- OpenAlex
- W2078972833
- Cited by
- 2,766
- References
- 35
- Citations by year
- 2026: 92 · 2025: 114 · 2024: 156 · 2023: 158 · 2022: 155 · 2021: 213 · 2020: 183 · 2019: 165 · 2018: 178 · 2017: 196 · 2016: 186 · 2015: 193 · 2014: 217 · 2013: 214 · 2012: 191
- FWCI
- 111.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- University of Pennsylvania
- Agios Pharmaceuticals
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL082950)
- National Cancer Institute (CA114737, R01CA105463, U54CA143798, U24CA114737, R01CA173636, U10CA021115, CA 21115)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, IDH2 mutation, acute myeloid leukemia, DNA hypermethylation, 2-hydroxyglutarate, TET2, hematopoietic differentiation, epigenetic dysregulation, stem/progenitor cells
- MeSH terms
- MDS1 and EVI1 Complex Locus Protein, Cell Differentiation, DNA-Binding Proteins, Humans, Hydroxylation, Isocitrate Dehydrogenase, Mutation, Phenotype, Proto-Oncogene Proteins, Proto-Oncogenes, Transcription Factors, Leukemia, Myeloid, Acute, DNA Methylation, Myeloid Cells, 5-Methylcytosine, Dioxygenases, GATA1 Transcription Factor, Gene Regulatory Networks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
